story of the week
Abiraterone Plus Prednisone Added to ADT and Docetaxel in De Novo Metastatic Castration-Sensitive Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
Lancet 2022 Apr 08;[EPub Ahead of Print], K Fizazi, S Foulon, J Carles, G Roubaud, R McDermott, A Fléchon, B Tombal, S Supiot, D Berthold, P Ronchin, G Kacso, G Gravis, F Calabro, JF Berdah, A Hasbini, M Silva, A Thiery-Vuillemin, I Latorzeff, L Mourey, B Laguerre, S Abadie-Lacourtoisie, E Martin, C El Kouri, A Escande, A Rosello, N Magne, F Schlurmann, F Priou, ME Chand-Fouche, SV Freixa, M Jamaluddin, I Rieger, A BossiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.